Rural clinics get help to catch diabetic eye disease early
NCT ID NCT05254535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a program called I-SITE can help rural health clinics use teleophthalmology (remote eye exams) to screen more diabetic patients for eye problems. Up to 10 health systems and 10,000 patients will take part. The goal is to see if screening rates improve over 24 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- I-SITE implementation program (coaching, technical assistance, and online toolkit)
- What this could lead to
- If successful, this could show a practical way to increase diabetic eye screening in rural areas, potentially preventing vision loss.
- What could go wrong
- This is a small, early-stage implementation study with only 10 health systems. Results may not apply to other settings, and it does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Health system serves rural patients as defined as those patients living in counties considered rural by the federal Office of Management and Budget (OMB) * Health system has an active clinical teleophthalmology program providing diabetic eye screening in primary care prior to study randomization * Health system agrees to share de-identified patient data at the requested time intervals Exclusion Criteria: * Health system does not serve a rural patient population * Health system has a diabetic eye screening rate of greater than 50% (e.g., above the national average) as it may limit the ability to measure improvement from I-SITE
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic retinopathy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UW School of Medicine and Public Health
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel make eye injections less painful?
- AI eye doctor: could software catch diabetic blindness sooner?
- Can eye scans reveal hidden clues about diabetes damage?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug aims to restore vision in Diabetes-Related swelling
- New eye drug aims to restore vision in Diabetes-Related swelling